Organization
Intercept Pharmaceuticals
11 clinical trials
8 abstracts
Clinical trial
A Study of INT 747 (6α-ethyl Chenodeoxycholic Acid (6-ECDCA)) in Combination With Ursodeoxycholic Acid (URSO®, UDCA) in Patients With Primary Biliary CirrhosisStatus: Terminated, Estimated PCD: 2009-08-01
Clinical trial
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary CholangitisStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated HepatitisStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic AcidStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary CholangitisStatus: Terminated, Estimated PCD: 2021-12-23
Clinical trial
A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study, With an Optional Open-Label Extension to Assess the Safety, Tolerability, and Pharmacokinetics of Obeticholic Acid in Pediatric Subjects With Biliary AtresiaStatus: Terminated, Estimated PCD: 2023-03-09
Clinical trial
Study Evaluating the Effectiveness of Obeticholic Acid on Hepatic Real-World Outcomes in Patients With Primary Biliary CholangitisStatus: Withdrawn, Estimated PCD: 2023-06-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisStatus: Completed, Estimated PCD: 2022-09-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid Compared to Placebo in Pediatric Subjects With Biliary Atresia, Post-hepatoportoenterostomyStatus: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic SteatohepatitisStatus: Terminated, Estimated PCD: 2023-09-15
Abstract
Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.Org: Department of Urologic Sciences, Vancouver General Hospital, Canada, BC Cancer - Vancouver Centre, BC,
Abstract
Unstructured EMR data hold the key to oncology studies: Methods for validating NLP-extracted phenotypes from EMR notes.Org: IQVIA, Boston Pharmaceuticals, MaaT Pharma, South Bend, Intercept Pharmaceuticals,
Abstract
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.Org: University of Wisconsin, Carbone Cancer Center, Madison, WI, Wigen Biomedicine Technology (Shanghai), University of Wisconsin Carbone Cancer Center,
Abstract
Impact of hyponatremia on multiple myeloma hospitalizations: A nationwide analysis.Org: Brooklyn Hospital Center, Brooklyn, NY, Brooklyn ImmunoTherapeutics, Nykode Therapeutics, The Brooklyn Hospital Center, New York, NY, New York Oncology Hematology PC,
Abstract
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.Org: Roswell Park Comprehensive Cancer Center, Buffalo, IL, Nykode Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa General Hospital,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Intercept Pharmaceuticals,
Abstract
The association of demographic factors and disease stage on palliative care (PC) referral rates and completion of advanced directives in a lung cancer (LC) patient population.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Intercept Pharmaceuticals, Indiana University School of Medicine Department of Medicine, IU Hematology/Oncology,
Clinical trial
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects With Primary Biliary CholangitisStatus: Not yet recruiting, Estimated PCD: 2025-01-01